Daiwa Securities Group Inc. Sells 20,015 Shares of Elanco Animal Health (NYSE:ELAN)

Daiwa Securities Group Inc. trimmed its position in shares of Elanco Animal Health (NYSE:ELAN) by 31.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,996 shares of the company’s stock after selling 20,015 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Elanco Animal Health were worth $1,170,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ELAN. Winthrop Partners WNY LLC bought a new position in shares of Elanco Animal Health during the third quarter worth $25,000. San Francisco Sentry Investment Group CA boosted its position in shares of Elanco Animal Health by 196.7% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,157 shares of the company’s stock worth $31,000 after purchasing an additional 767 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Elanco Animal Health during the second quarter worth $32,000. Toth Financial Advisory Corp bought a new stake in Elanco Animal Health in the 3rd quarter valued at $33,000. Finally, Capital Investment Advisory Services LLC lifted its position in Elanco Animal Health by 1,501.4% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock valued at $36,000 after acquiring an additional 1,051 shares in the last quarter.

ELAN opened at $26.57 on Tuesday. The stock has a market capitalization of $9.96 billion, a P/E ratio of 22.52 and a beta of 0.69. Elanco Animal Health has a 12 month low of $25.51 and a 12 month high of $35.46. The firm’s fifty day simple moving average is $26.86 and its 200 day simple moving average is $30.24. The company has a current ratio of 3.07, a quick ratio of 1.71 and a debt-to-equity ratio of 0.45.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.26 by $0.04. Elanco Animal Health had a net margin of 3.04% and a return on equity of 7.89%. The business had revenue of $771.30 million for the quarter, compared to analysts’ expectations of $765.85 million. During the same period in the previous year, the firm posted $0.29 EPS. The firm’s revenue was up 1.3% compared to the same quarter last year. On average, equities research analysts predict that Elanco Animal Health will post 1.07 EPS for the current fiscal year.

In other Elanco Animal Health news, major shareholder Dawei Li purchased 1,384,717 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average cost of $1.05 per share, with a total value of $1,453,952.85. Also, CEO Jeffrey N. Simmons purchased 75,750 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $26.55 per share, for a total transaction of $2,011,162.50. Following the completion of the transaction, the chief executive officer now directly owns 470,006 shares in the company, valued at $12,478,659.30. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,497,497 shares of company stock worth $4,457,115 over the last three months. Insiders own 0.04% of the company’s stock.

Several equities research analysts recently commented on ELAN shares. ValuEngine raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Morgan Stanley raised shares of Elanco Animal Health from an “equal” rating to a “weight” rating and cut their price objective for the company from $34.00 to $32.00 in a research report on Thursday, November 7th. Zacks Investment Research cut shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 15th. Cleveland Research reaffirmed a “hold” rating on shares of Elanco Animal Health in a research report on Thursday, September 26th. Finally, Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research report on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Elanco Animal Health has an average rating of “Hold” and an average price target of $33.41.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

See Also: Green Investing

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.